Ovarian cancer is the sixth most common cancer in women from Scotland. Now they have a new option, after The Scottish Medicines Consortium approved bevacizumab (Avastin) combined with paclitaxel for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy. Manufacturers Roche remark that adding bevacizumab to chemotherapy increased median progression free survival from 3.4 months to 6.7 months.